Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D: N-Glycan Subtypes in Host-Pathogen Interactions.

Identifieur interne : 000001 ( 1957/Analysis ); précédent : 000000; suivant : 000002

Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D: N-Glycan Subtypes in Host-Pathogen Interactions.

Auteurs : Lisa M. Parsons [États-Unis] ; Yanming An [États-Unis] ; Li Qi [États-Unis] ; Mitchell R. White [États-Unis] ; Roosmarijn Van Der Woude [Pays-Bas] ; Kevan L. Hartshorn [États-Unis] ; Jeffery K. Taubenberger [États-Unis] ; Robert P. De Vries [Pays-Bas] ; John F. Cipollo

Source :

RBID : pubmed:31826991

Abstract

Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites can be removed from the lung by pulmonary surfactant protein D (SP-D). Little is known about HA head glycosylation of low-pathogenicity avian influenza virus (LPAIV) subtypes. These can pose a pandemic threat through reassortment and emergence in human populations. Since the presence of head region high-mannose glycosites dictates SP-D activity, the ability to predict these glycosite glycan subtypes may be of value. Here, we investigate the activities of two recombinant human SP-D forms against representative LPAIV strains, including H2N1, H5N1, H6N1, H11N9, an avian H3N8, and a human seasonal H3N2 subtype. Using mass spectrometry, we determined the glycan subclasses and heterogeneities at each head glycosylation site. Sequence alignment and molecular structure analysis of the HAs were performed for LPAIV strains in comparison to seasonal H3N2 and avian H3N8. Intramolecular contacts were determined between the protein backbone and glycosite glycan based on available three-dimensional structure data. We found that glycosite "N165" (H3 numbering) is occupied by high-mannose glycans in H3 HA but by complex glycans in all LPAIV HAs. SP-D was not active on LPAIV but was on H3 HAs. Since SP-D affinity for influenza HA depends on the presence of high-mannose glycan on the head region, our data demonstrate that SP-D may not protect against virus containing these HA subtypes. Our results also demonstrate that glycan subtype can be predicted at some glycosites based on sequence comparisons and three-dimensional structural analysis.IMPORTANCE Low-pathogenicity avian influenza virus (LPAIV) subtypes can reassort with circulating human strains and pandemic viruses can emerge in human populations, as was seen in the 1957 pandemic, in which an H2 virus reassorted with the circulating H1N1 to create a novel H2N2 genotype. Lung surfactant protein D (SP-D), a key factor in first-line innate immunity defense, removes influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s). While it is known that both H1 and H3 HAs have one or more key high-mannose glycosites in the head region, little is known about similar glycosylation of LPAIV strains H2N1, H5N1, H6N1, or H11N9, which may pose future health risks. Here, we demonstrate that the hemagglutinins of LPAIV strains do not have the required high-mannose glycans and do not interact with SP-D, and that sequence analysis can predict glycan subtype, thus predicting the presence or absence of this virulence marker.

DOI: 10.1128/JVI.01951-19
PubMed: 31826991


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:31826991

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D:
<i>N</i>
-Glycan Subtypes in Host-Pathogen Interactions.</title>
<author>
<name sortKey="Parsons, Lisa M" sort="Parsons, Lisa M" uniqKey="Parsons L" first="Lisa M" last="Parsons">Lisa M. Parsons</name>
<affiliation wicri:level="2">
<nlm:affiliation>Food and Drug Administration, Center for Biologics Evaluation and Research, Division of Bacterial, Parasitic and Allergenic Products, Silver Spring, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Food and Drug Administration, Center for Biologics Evaluation and Research, Division of Bacterial, Parasitic and Allergenic Products, Silver Spring, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="An, Yanming" sort="An, Yanming" uniqKey="An Y" first="Yanming" last="An">Yanming An</name>
<affiliation wicri:level="2">
<nlm:affiliation>Food and Drug Administration, Center for Drug Evaluation and Research, DBRRII, Silver Spring, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Food and Drug Administration, Center for Drug Evaluation and Research, DBRRII, Silver Spring, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Qi, Li" sort="Qi, Li" uniqKey="Qi L" first="Li" last="Qi">Li Qi</name>
<affiliation wicri:level="2">
<nlm:affiliation>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="White, Mitchell R" sort="White, Mitchell R" uniqKey="White M" first="Mitchell R" last="White">Mitchell R. White</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts</wicri:regionArea>
<placeName>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Van Der Woude, Roosmarijn" sort="Van Der Woude, Roosmarijn" uniqKey="Van Der Woude R" first="Roosmarijn" last="Van Der Woude">Roosmarijn Van Der Woude</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName>
<settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author>
<name sortKey="Hartshorn, Kevan L" sort="Hartshorn, Kevan L" uniqKey="Hartshorn K" first="Kevan L" last="Hartshorn">Kevan L. Hartshorn</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts</wicri:regionArea>
<placeName>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Taubenberger, Jeffery K" sort="Taubenberger, Jeffery K" uniqKey="Taubenberger J" first="Jeffery K" last="Taubenberger">Jeffery K. Taubenberger</name>
<affiliation wicri:level="2">
<nlm:affiliation>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="De Vries, Robert P" sort="De Vries, Robert P" uniqKey="De Vries R" first="Robert P" last="De Vries">Robert P. De Vries</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName>
<settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author>
<name sortKey="Cipollo, John F" sort="Cipollo, John F" uniqKey="Cipollo J" first="John F" last="Cipollo">John F. Cipollo</name>
<affiliation>
<nlm:affiliation>Food and Drug Administration, Center for Drug Evaluation and Research, DBRRII, Silver Spring, Maryland, USA john.cipollo@fda.hhs.gov.</nlm:affiliation>
<wicri:noCountry code="subField">USA john.cipollo@fda.hhs.gov.</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31826991</idno>
<idno type="pmid">31826991</idno>
<idno type="doi">10.1128/JVI.01951-19</idno>
<idno type="wicri:Area/PubMed/Corpus">000003</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000003</idno>
<idno type="wicri:Area/PubMed/Curation">000003</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000003</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000001</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000001</idno>
<idno type="wicri:Area/Ncbi/Merge">001037</idno>
<idno type="wicri:Area/Ncbi/Curation">001037</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001037</idno>
<idno type="wicri:Area/Main/Merge">000010</idno>
<idno type="wicri:Area/Main/Curation">000010</idno>
<idno type="wicri:Area/Main/Exploration">000010</idno>
<idno type="wicri:Area/1957/Extraction">000001</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D:
<i>N</i>
-Glycan Subtypes in Host-Pathogen Interactions.</title>
<author>
<name sortKey="Parsons, Lisa M" sort="Parsons, Lisa M" uniqKey="Parsons L" first="Lisa M" last="Parsons">Lisa M. Parsons</name>
<affiliation wicri:level="2">
<nlm:affiliation>Food and Drug Administration, Center for Biologics Evaluation and Research, Division of Bacterial, Parasitic and Allergenic Products, Silver Spring, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Food and Drug Administration, Center for Biologics Evaluation and Research, Division of Bacterial, Parasitic and Allergenic Products, Silver Spring, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="An, Yanming" sort="An, Yanming" uniqKey="An Y" first="Yanming" last="An">Yanming An</name>
<affiliation wicri:level="2">
<nlm:affiliation>Food and Drug Administration, Center for Drug Evaluation and Research, DBRRII, Silver Spring, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Food and Drug Administration, Center for Drug Evaluation and Research, DBRRII, Silver Spring, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Qi, Li" sort="Qi, Li" uniqKey="Qi L" first="Li" last="Qi">Li Qi</name>
<affiliation wicri:level="2">
<nlm:affiliation>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="White, Mitchell R" sort="White, Mitchell R" uniqKey="White M" first="Mitchell R" last="White">Mitchell R. White</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts</wicri:regionArea>
<placeName>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Van Der Woude, Roosmarijn" sort="Van Der Woude, Roosmarijn" uniqKey="Van Der Woude R" first="Roosmarijn" last="Van Der Woude">Roosmarijn Van Der Woude</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName>
<settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author>
<name sortKey="Hartshorn, Kevan L" sort="Hartshorn, Kevan L" uniqKey="Hartshorn K" first="Kevan L" last="Hartshorn">Kevan L. Hartshorn</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts</wicri:regionArea>
<placeName>
<region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Taubenberger, Jeffery K" sort="Taubenberger, Jeffery K" uniqKey="Taubenberger J" first="Jeffery K" last="Taubenberger">Jeffery K. Taubenberger</name>
<affiliation wicri:level="2">
<nlm:affiliation>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="De Vries, Robert P" sort="De Vries, Robert P" uniqKey="De Vries R" first="Robert P" last="De Vries">Robert P. De Vries</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName>
<settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author>
<name sortKey="Cipollo, John F" sort="Cipollo, John F" uniqKey="Cipollo J" first="John F" last="Cipollo">John F. Cipollo</name>
<affiliation>
<nlm:affiliation>Food and Drug Administration, Center for Drug Evaluation and Research, DBRRII, Silver Spring, Maryland, USA john.cipollo@fda.hhs.gov.</nlm:affiliation>
<wicri:noCountry code="subField">USA john.cipollo@fda.hhs.gov.</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Seasonal influenza carrying key hemagglutinin (HA) head region glycosylation sites can be removed from the lung by pulmonary surfactant protein D (SP-D). Little is known about HA head glycosylation of low-pathogenicity avian influenza virus (LPAIV) subtypes. These can pose a pandemic threat through reassortment and emergence in human populations. Since the presence of head region high-mannose glycosites dictates SP-D activity, the ability to predict these glycosite glycan subtypes may be of value. Here, we investigate the activities of two recombinant human SP-D forms against representative LPAIV strains, including H2N1, H5N1, H6N1, H11N9, an avian H3N8, and a human seasonal H3N2 subtype. Using mass spectrometry, we determined the glycan subclasses and heterogeneities at each head glycosylation site. Sequence alignment and molecular structure analysis of the HAs were performed for LPAIV strains in comparison to seasonal H3N2 and avian H3N8. Intramolecular contacts were determined between the protein backbone and glycosite glycan based on available three-dimensional structure data. We found that glycosite "N165" (H3 numbering) is occupied by high-mannose glycans in H3 HA but by complex glycans in all LPAIV HAs. SP-D was not active on LPAIV but was on H3 HAs. Since SP-D affinity for influenza HA depends on the presence of high-mannose glycan on the head region, our data demonstrate that SP-D may not protect against virus containing these HA subtypes. Our results also demonstrate that glycan subtype can be predicted at some glycosites based on sequence comparisons and three-dimensional structural analysis.
<b>IMPORTANCE</b>
Low-pathogenicity avian influenza virus (LPAIV) subtypes can reassort with circulating human strains and pandemic viruses can emerge in human populations, as was seen in the 1957 pandemic, in which an H2 virus reassorted with the circulating H1N1 to create a novel H2N2 genotype. Lung surfactant protein D (SP-D), a key factor in first-line innate immunity defense, removes influenza type A virus (IAV) through interaction with hemagglutinin (HA) head region high-mannose glycan(s). While it is known that both H1 and H3 HAs have one or more key high-mannose glycosites in the head region, little is known about similar glycosylation of LPAIV strains H2N1, H5N1, H6N1, or H11N9, which may pose future health risks. Here, we demonstrate that the hemagglutinins of LPAIV strains do not have the required high-mannose glycans and do not interact with SP-D, and that sequence analysis can predict glycan subtype, thus predicting the presence or absence of this virulence marker.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Pays-Bas</li>
<li>États-Unis</li>
</country>
<region>
<li>Maryland</li>
<li>Massachusetts</li>
<li>Utrecht (province)</li>
</region>
<settlement>
<li>Utrecht</li>
</settlement>
<orgName>
<li>Université d'Utrecht</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Cipollo, John F" sort="Cipollo, John F" uniqKey="Cipollo J" first="John F" last="Cipollo">John F. Cipollo</name>
</noCountry>
<country name="États-Unis">
<region name="Maryland">
<name sortKey="Parsons, Lisa M" sort="Parsons, Lisa M" uniqKey="Parsons L" first="Lisa M" last="Parsons">Lisa M. Parsons</name>
</region>
<name sortKey="An, Yanming" sort="An, Yanming" uniqKey="An Y" first="Yanming" last="An">Yanming An</name>
<name sortKey="Hartshorn, Kevan L" sort="Hartshorn, Kevan L" uniqKey="Hartshorn K" first="Kevan L" last="Hartshorn">Kevan L. Hartshorn</name>
<name sortKey="Qi, Li" sort="Qi, Li" uniqKey="Qi L" first="Li" last="Qi">Li Qi</name>
<name sortKey="Taubenberger, Jeffery K" sort="Taubenberger, Jeffery K" uniqKey="Taubenberger J" first="Jeffery K" last="Taubenberger">Jeffery K. Taubenberger</name>
<name sortKey="White, Mitchell R" sort="White, Mitchell R" uniqKey="White M" first="Mitchell R" last="White">Mitchell R. White</name>
</country>
<country name="Pays-Bas">
<region name="Utrecht (province)">
<name sortKey="Van Der Woude, Roosmarijn" sort="Van Der Woude, Roosmarijn" uniqKey="Van Der Woude R" first="Roosmarijn" last="Van Der Woude">Roosmarijn Van Der Woude</name>
</region>
<name sortKey="De Vries, Robert P" sort="De Vries, Robert P" uniqKey="De Vries R" first="Robert P" last="De Vries">Robert P. De Vries</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/1957/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000001 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/1957/Analysis/biblio.hfd -nk 000001 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    1957
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:31826991
   |texte=   Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D: N-Glycan Subtypes in Host-Pathogen Interactions.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/1957/Analysis/RBID.i   -Sk "pubmed:31826991" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/1957/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021